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low-resource settings, and to ensure 
that this and similar new technologies 
can be appropriately and eﬀ ectively 
implemented. Use of the Xpert assay 
will probably increase costs for national 
programmes; commitment by national 
governments and donors to consider 
this cost in their budgets is mandatory.
Introduction of the Xpert MTB/
RIF assay marks the beginning of the 
revolution of tuberculosis diagnostics 
in the early part of the 21st century, but 
the hard part is still to come.
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Authors’ reply
In response to our paper on Xpert 
MTB/RIF,1 Grant Theron and colleagues 
point out that a proportion of patients 
with tuberculosis, importantly some 
infected with HIV, will not be detected 
by Xpert testing. Clearly patients who 
expectorate very low concentrations 
of organisms could be misdiagnosed 
with all existing methods. In the case 
of microscopy and HIV-associated 
tuberculosis, this dilemma is acute. 
Xpert testing greatly diminishes, but 
does not eliminate, the likelihood 
that some tuberculosis will be missed. 
Since no test is 100% sensitive, health 
workers confronted with negative 
results from patients with suspected 
disease must: (1) retest a new sample, 
(2) test with alternative methods, 
or (3) treat on clinical bases.  Xpert, 
despite sensitivity similar to solid 
culture, cannot resolve this dilemma.
Having said that, Theron and 
colleagues’ calculation of negative 
predictive values from our study does 
not take into account the fact that 
these values are heavily dependent 
on local prevalence of disease. The 
demonstration study took place in 
six diﬀ erent countries with diﬀ erent 
prevalences of HIV infection and 
tuberculosis. The aggregate statistics 
published in our paper were balanced 
by stratiﬁ cation over these diﬀ erent 
study sites. Theron and colleagues base 
their conclusions on a tuberculosis 
prevalence of 35% in patients with HIV 
infection and 31% in patients without 
HIV infection (an average of each across 
sites). This particular combination 
was not identiﬁ ed in any single site 
and so the resulting aggregate is an 
oversimpliﬁ cation. The diﬀ erence in 
sensitivity would, for example, not be 
signiﬁ cant if one applied 30% disease 
prevalence in both groups.
Fulvio Salvo and colleagues stress 
that the need for phenotypic drug 
susceptibility testing (DST) will not 
disappear with Xpert implementation. 
We agree, but note that, because DST 
availability is limited, Xpert provides 
an eﬀ ective mechanism to focus 
resources on patients at high risk of 
drug resistance. Both phenotypic 
and genotypic testing result in some 
false calls: errors in DST for rifampicin 
occur with a frequency of 1–3% even 
in supranational laboratories.2 In the 
quoted Dharamsala study, seven of 
45 tuberculosis cases were rifampicin-
susceptible on DST but resistant by 
Xpert by means of the then-available 
instrument software. This unusually 
high false-positive rate merits fur-
ther investigation. Unfortunately rpoB 
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Katharina Kranzer’s Comment1 
accompanying the paper by Catharina 
Boehme and colleagues2 highlights 
important limitations of the Xpert 
MTB/RIF assay, such as its shortfalls 
as an ideal point-of-care test and its 
use for detection of drug-resistant 
tuberculosis.
However, a shift of focus is now 
urgently required; the accuracy of 
the assay has been addressed.2,3 We 
need to move on and assess its cost-
eﬀ ectiveness and how it will change the 
performance of national tuberculosis 
programmes in terms of detection 
rates and management of resistant 
forms of Mycobacterium tuberculosis. 
Although self-evident for any new 
test, it might be prudent to recall that 
an operational assess ment should be 
done independently of the funders, 
developers, and manufacturers of 
the assay. Independent high-quality 
operational research in diﬀ erent 
geographical and economic settings 
is also required to show where, when, 
and how the new assay will provide 
clear advantages for health-care 
systems and patients.4
Although the Xpert MTB/RIF assay 
is recommended for screening of 
drug-resistant tuberculosis and for 
populations infected with HIV,5 its 
high sensitivity in smear-negative 
cases could support other uses, such as 
for biomarkers of tuberculosis disease 
activity or cure.
Creativity and innovative solutions 
are needed to ﬁ ll structural gaps in 
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sequence information from these 
strains was not available. False-positive 
Xpert rifampicin resistance occurred 
during our demonstration projects, 
and triggered a root-cause analysis by 
the manufacturer, and a subsequent 
development plan to improve 
reagents, microﬂ uidics, and software. 
Software solutions have been only 
partly successful, but we expect that 
the other reﬁ nements will eliminate 
most remaining false-resistance calls. 
Ideally, Xpert should equal or surpass 
DST reliability. In settings with a low 
prevalence of multidrug-resistant 
(MDR) tuberculosis, even low error 
rates would aﬀ ect predictive values, 
and repeat molecular or phenotypic 
testing might be required. Countries 
will need to decide, depending on 
prevalence of MDR tuberculosis, 
second-line treat ment availability, 
budget, pheno typic DST capacity, 
and how they handle Xpert results 
suggesting MDR tuberculosis.
Giovanni Ferrara and colleagues 
correctly point out that performance 
data provide an incomplete picture of 
a new diagnostic’s usefulness. We also 
agree that implementing improved 
tuberculosis diagnostic testing will 
require substantial investment. Fortu-
nately, Xpert MTB/RIF testing gets us 
very close to the goal of universal access 
to culture and DST without the need 
to construct unsustainable biosafety 
laboratories or wait for culture results.
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Sharing information on 
adverse events
It is highly regrettable that you ran the 
letter by Koichiro Yuji and colleagues 
(May 14, p 1654)1 which labels a 
report that ran in Asahi Shimbun 
as “misleading”. The article from 
Oct 15, 2010,2 was written from 
the viewpoint of protecting trial 
participants, and critically appraised a 
clinical trial at the Institute of Medical 
Science, University of Tokyo (IMSUT, 
to which one of the authors of the 
letter is aﬃ  liated) and other sites. 
Yuji and colleagues’ letter contains 
serious misinterpretations of facts.
Our article reported that, despite 
a serious adverse event developing 
during the clinical trial of a cancer 
peptide vaccine at the IMSUT Hospital, 
IMSUT, as the vaccine developer, failed 
to report the incident to other clinical 
trial sites which had been supplied 
with the vaccine. The point of the 
article was to raise the question as to 
the appropriateness of the handling 
of safety information.
Yuji and colleagues wrote: “The 
newspaper seems to have interpreted a 
‘serious adverse event’ as a ‘signiﬁ cant 
complication’ of the cancer vaccine.” 
In fact, nothing in the article indicates 
confusion between an adverse event 
and a complication.
Yuji and colleagues also wrote: “In 
an Editorial, the newspaper went on 
to accuse the researchers of hiding the 
adverse event, and likened them to 
doctors in Nazi Germany.” This sentence 
is also based on a misinterpretation. The 
Asahi Shimbun merely stated that the 
Declaration of Helsinki was developed 
as a response to human experiments 
carried out by the Nazis—it did not liken 
the clinical researchers to the Nazis.
I am the Editor in Chief of the Science and Medical 
News Section of the Asahi Shimbun.
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Blood-cell banking for 
workers at the 
Fukushima Daiichi 
nuclear power plant
Tetsuya Tanimoto and colleagues 
(April 30, p 1489)1 propose collection 
and storage of blood cells (equivalent 
to bone-marrow cells) from nuclear 
workers at the Fukushima nuclear 
power station, Japan, for possible use 
after accidental exposure to high-dose 
ionising radiation. We think that this 
recommendation is well intentioned 
but ill-advised for several reasons.
First, the best strategy in any 
nuclear or radiation exposure event is 
prevention. Workers at Fukushima are 
carefully monitored with dosimeters 
that detect external and internal 
radiation exposure levels. There are 
also numerous stable and robotic 
environmental monitoring devices.
Second, transplantation of blood 
or bone-marrow cells is relevant only 
if there is exposure to uniform, high-
dose, whole-body radiation. Such 
exposure requires that the person 
be at a substantial distance from the 
radiation source (probably 3–4 m). Our 
study of the geometry of the Fukushima 
nuclear power station makes this type 
of exposure exceedingly unlikely.
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